Rocketvax has signed a letter of intent with the U.S. National Institutes of Health (NIH) for a clinical trial as part of the Project NextGen initiative.
Organizations Involved
Emergent BioSolutions, U.S. National Institutes of Health
Company Description
Rocketvax Ltd is focused on developing next-generation vaccines using proprietary technology, including a live-attenuated nasal spray SARS-CoV-2 vaccine that has shown superior efficacy compared to mRNA COVID-19 vaccines in animal studies.
Market
Infectious diseases, cancer, and autoimmune disorders